Related Experiment Video
Updated: Jul 4, 2026
11:30
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Calcimimetics in CKD-results from recent clinical studies
Pediatric Nephrology (Berlin, Germany)
|July 3, 2008
Summary
Cinacalcet effectively lowers parathyroid hormone (PTH) in secondary hyperparathyroidism (sHPT) patients with chronic kidney disease (CKD). This calcimimetic offers improved management of CKD-mineral and bone disorder (CKD-MBD) markers across various CKD stages.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Secondary hyperparathyroidism (sHPT) is a common complication in chronic kidney disease (CKD), contributing to vascular calcification and renal osteodystrophy (CKD-BMD).
- sHPT in CKD patients is associated with increased cardiovascular mortality.
- The calcium-sensing receptor (CaR) on parathyroid glands is a therapeutic target for sHPT.
Discussion:
- Calcimimetics, such as cinacalcet, activate the CaR, enhancing calcium sensitivity and reducing parathyroid hormone (PTH) secretion.
- Clinical studies demonstrate cinacalcet's efficacy in lowering PTH levels in dialysis patients, with some achieving NKF-KDOQI targets.
- Evidence suggests cinacalcet can reduce PTH in CKD stages 3-4, though phosphate levels may increase; it also shows promise in post-transplant hyperparathyroidism and pediatric dialysis patients.
Key Insights:
- Cinacalcet is effective in reducing PTH in hemodialysis patients with sHPT.
- In predialysis CKD patients (stages 3-4), cinacalcet lowers PTH but may elevate phosphate.
- Calcimimetics show potential for managing hypercalcemia and reducing PTH post-renal transplantation.
Outlook:
- Further research is needed to optimize cinacalcet use in non-dialysis CKD patients, particularly regarding phosphate management.
- Investigating long-term cardiovascular outcomes in CKD patients treated with cinacalcet is crucial.
- Exploring novel calcimimetics and combination therapies could offer improved sHPT management in CKD.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:18Chronic Kidney Disease IV: Nursing Management
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...